Skip to main content

Cookies

We use cookies on our website to give you the most relevant experience possible. If you continue browsing, we consider that you have accepted the cookies.

Contact Us

Vascular Biogenics Ltd.
(VBL Therapeutics)

Israel

8 HaSatat St.
Modi'in, Israel 7178106

Phone
+972-8-9935000
Fax
+972-8-9935001

New York

1 Blue Hill Plaza
Pearl River, NY 10965 USA

Phone
+1-845-474-8411
General Inquiries
Investor Relations Inquiries

Learn More

Lab technicians in lab hoodies, working in VBL’s facility in Modiin, Israel.
VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications expected to enter Phase 1 in the first quarter of 2023, that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.
Copyright © 2025 VBL Therapeutics.
Terms and Conditions. Privacy Policy. Accessibility.